Ardelyx Inc (ARDX NASDAQ) stock market data APIs
$6.4958
0.1(1.5%)
as of September 15, 2025
Try our APIs with
free plan!
Ardelyx Inc Financial Data Overview
Price chart is built with
Anychart
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Prev. Close
6.4958
Open
6.5985
High
6.6432
Low
6.5122
52 wk Range
3.21-7.18
Market Cap
1 574 M
Shares Outstanding
241 M
Revenue
386 M
EPS
-0.08
Beta
0.732
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Ardelyx Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 386 M
- EBITDA: -38 094 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-30
- EPS/Forecast: -0.1219
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News
New
Implied XBI Analyst Target Price: $142
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, an...
Ardelyx, Inc. (ARDX) Strengthens Global Reach with Kyowa Kirin Deal
We recently published 10 Best Biotech Stocks to Buy Under $10. Ardelyx, Inc. stands fourth among them. Ardelyx, Inc. (NASDAQ:ARDX) stands fourth on our list among the best biotech stocks. It is a bio...
Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors
EMERYVILLE, Calif., August 12, 2025--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appoin...
Ardelyx raises 2025 IBSRELA revenue guidance to $250M–$260M amid sustained demand growth
Earnings Call Insights: Ardelyx (ARDX) Q2 2025 MANAGEMENT VIEW * Michael G. Raab, President and CEO, emphasized the company's strong quarter, stating "We generated $97.7 million in total revenue, ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
